ES2162503T3 - Derivados diaza-espiro(3,5)nonanos. - Google Patents

Derivados diaza-espiro(3,5)nonanos.

Info

Publication number
ES2162503T3
ES2162503T3 ES99110943T ES99110943T ES2162503T3 ES 2162503 T3 ES2162503 T3 ES 2162503T3 ES 99110943 T ES99110943 T ES 99110943T ES 99110943 T ES99110943 T ES 99110943T ES 2162503 T3 ES2162503 T3 ES 2162503T3
Authority
ES
Spain
Prior art keywords
sup
lower alkyl
hydrogen
decahydro
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99110943T
Other languages
English (en)
Spanish (es)
Inventor
Geo Adam
Andrea Cesura
Francois Jenck
Sabine Kolczewski
Stephan Roever
Jurgen Wichmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2162503T3 publication Critical patent/ES2162503T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
ES99110943T 1998-06-12 1999-06-07 Derivados diaza-espiro(3,5)nonanos. Expired - Lifetime ES2162503T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110804 1998-06-12

Publications (1)

Publication Number Publication Date
ES2162503T3 true ES2162503T3 (es) 2001-12-16

Family

ID=8232114

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99110943T Expired - Lifetime ES2162503T3 (es) 1998-06-12 1999-06-07 Derivados diaza-espiro(3,5)nonanos.

Country Status (28)

Country Link
US (1) US6113527A (Direct)
EP (1) EP0970957B1 (Direct)
JP (1) JP3286268B2 (Direct)
KR (1) KR100344732B1 (Direct)
CN (1) CN1107066C (Direct)
AR (1) AR019859A1 (Direct)
AT (1) ATE204279T1 (Direct)
AU (1) AU743983B2 (Direct)
BR (1) BR9902651A (Direct)
CA (1) CA2274202A1 (Direct)
DE (1) DE69900220T2 (Direct)
DK (1) DK0970957T3 (Direct)
ES (1) ES2162503T3 (Direct)
HR (1) HRP990188A2 (Direct)
HU (1) HU220894B1 (Direct)
ID (1) ID23304A (Direct)
IL (1) IL130377A0 (Direct)
MA (1) MA26644A1 (Direct)
NO (1) NO312590B1 (Direct)
NZ (1) NZ336189A (Direct)
PE (1) PE20000548A1 (Direct)
PL (1) PL333695A1 (Direct)
PT (1) PT970957E (Direct)
SG (1) SG79259A1 (Direct)
SI (1) SI0970957T1 (Direct)
TR (1) TR199901381A2 (Direct)
YU (1) YU26499A (Direct)
ZA (1) ZA993852B (Direct)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
JP4056977B2 (ja) * 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
JP2005289816A (ja) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
BR0312414A (pt) 2002-07-05 2005-05-10 Targacept Inc Compostos de n-aril diazaespirociclico e métodos para a preparação e uso dos mesmos
EP1601674B1 (en) * 2002-09-09 2012-08-08 Janssen Pharmaceutica NV Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
EP1784184A2 (en) * 2004-08-20 2007-05-16 Targacept, Inc. The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
US8703948B2 (en) * 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
MX2009011006A (es) * 2007-04-09 2009-11-02 Janssen Pharmaceutica Nv Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
KR101704226B1 (ko) 2015-06-30 2017-02-07 현대자동차주식회사 자동차의 쿼터글라스 어셈블리
EP4452416A1 (en) * 2021-12-22 2024-10-30 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756743A (en) * 1996-04-10 1998-05-26 Hoechst Marion Roussel Inc. Spiro cyclopent b!indole-piperidines!

Also Published As

Publication number Publication date
HU220894B1 (en) 2002-06-29
IL130377A0 (en) 2000-06-01
YU26499A (sh) 2002-09-19
BR9902651A (pt) 2000-05-16
NO992873D0 (no) 1999-06-11
EP0970957B1 (en) 2001-08-16
AU743983B2 (en) 2002-02-14
NO992873L (no) 1999-12-13
HRP990188A2 (en) 2000-02-29
NO312590B1 (no) 2002-06-03
TR199901381A3 (tr) 2000-01-21
JP3286268B2 (ja) 2002-05-27
SI0970957T1 (Direct) 2001-12-31
ZA993852B (en) 1999-12-13
KR100344732B1 (ko) 2002-07-19
PE20000548A1 (es) 2000-07-15
US6113527A (en) 2000-09-05
PL333695A1 (en) 1999-12-20
CA2274202A1 (en) 1999-12-12
HU9901911D0 (en) 1999-08-30
PT970957E (pt) 2002-02-28
DK0970957T3 (da) 2001-12-03
AR019859A1 (es) 2002-03-20
JP2000053679A (ja) 2000-02-22
DE69900220D1 (de) 2001-09-20
ID23304A (id) 2000-04-05
HUP9901911A1 (hu) 2000-05-28
DE69900220T2 (de) 2002-05-08
MA26644A1 (fr) 2004-12-20
TR199901381A2 (xx) 2000-01-21
ATE204279T1 (de) 2001-09-15
KR20000006060A (ko) 2000-01-25
CN1242366A (zh) 2000-01-26
EP0970957A1 (en) 2000-01-12
AU3498799A (en) 1999-12-23
CN1107066C (zh) 2003-04-30
SG79259A1 (en) 2001-03-20
NZ336189A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
ES2162503T3 (es) Derivados diaza-espiro(3,5)nonanos.
UY26276A1 (es) 1,2,4,5- tetrahidro-benzo (d) azepinas ley 17164
TWI255807B (en) Therapeutic agents
UY26043A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
UY26872A1 (es) Derivados de la 4- fenil piridina
PE20100093A1 (es) Derivados de acetileno
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
ES2133769T3 (es) Procedimiento para la sintesis diastereoselectiva de analogos de nucleosidos.
EA200100428A1 (ru) Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
ES2165520T3 (es) Compuestos parasiticidas.
RU2006105777A (ru) Индол-6-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6
ATE180476T1 (de) 5h-indeno(1,2-b>pyrazin-2,3-dion-derivate antagonisten der ampa und nmda rezeptoren
DE69323712D1 (de) Indol derivate zur behandlung von migräne
PT957080E (pt) Novos derivados de etilamina
MX9602979A (es) Compuestos heterociclicos terapeuticos.
PE135299A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona
ES2123873T3 (es) Pirrolocarbazol.
MY146599A (en) New azetidine compounds
HUP0001165A2 (hu) NK1 és NK2 antagonista hatású acil-amino-alkil-amid-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
PA8563601A1 (es) Acidos-3-(imidazolil)-2- alcoxipropanoicos
DE60327709D1 (de) Fusionierte cycloalkyl amid- und carbonsäure-derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie
PE20011260A1 (es) Derivados de sulfonamida

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 970957

Country of ref document: ES